

NOSF absorbent lipido-colloid dressing* Results of an observational study in Germany

Dr. med. Karl-Christian Münter

Group practice, Bramfelder Chaussee 200, 22177 Hamburg

OBJECTIVE

The **new NOSF absorbent lipido-colloid dressing*** is a new wound dressing derived from Technology Lipido-Colloid (TLC), combining the benefits of an absorbent foam with a new compound Nano-Oligosaccharide Factor (NOSF). This new dressing has been recognized for its matrix-metallo-proteinases (MMP) inhibition activity in wounds at risk of delayed healing. An observational study in outpatients was carried out to demonstrate the efficacy and tolerance of this new dressing.

MATERIAL AND METHODS

An observational study was carried out in Germany between September 2007 and April 2008 with general practitioners, surgeons and dermatologists to demonstrate the efficacy, tolerance and acceptability of the **NOSF absorbent lipido-colloid dressing*** in a large patient population. The physician could include any type of wound if he/she felt that the treatment was appropriate. A questionnaire to be documented by the patient also provided details according to the acceptability and the satisfaction with the dressing. The main evaluation criterion was the evolution of the wound surface area which was documented at inclusion, in four following visits and at the end of the treatment by the physician.

RESULTS

483 centers included 2052 patients. 55.1% of patients were female patients, the mean age was 68.9 years old. 1007 patients questionnaire were returned, and 59% of them were completed with the aid of another person. A high number of patients suffered from diabetes (43.5%), 22.4% of patients were clinically obese, 21.3% of patients were immobile and 19.1% presented congestive cardiac.

The most frequent type of wound was venous leg ulcer (59% of patients) (Fig. 1). The median wound duration was 90 days (mean value: 338 days).. On average, the wounds were treated with the **NOSF absorbent lipido-colloid dressing*** during 51 days and their progress was evaluated. Dressings used previously are shown in Figure 2. The median wound surface area was 10 cm² at inclusion. At the end of the treatment, a median reduction of 75% to 2 cm² was observed (Fig. 3). 28.1% of wounds healed and 73.5% of the physicians judged the treatment with the **NOSF absorbent lipido-colloid dressing*** as "extremely useful".

The dressing was assessed as "very comfortable" or "comfortable" by 96% of the patients, and 93.5% of patients were "very satisfied" or "satisfied" by the dressing.

BASELINE POPULATION

Figure 1: Types of wounds treated





Figure 2: Dressings used previously to observational study. Sum > 100 because several answers were possible.



Amongst patients presenting with venous leg ulcers, 45.5% of the patients received compression therapy with single-layer short stretch bandages, 30.1% of patients were treated with two or multi-layer compression bandages; and 29.5% wore a compression stocking.

Figure 3: Evolution of wound surface absolute median values Visit (1= T0. 6 = final visit)





Figure 4: Evolution of wound surface area per type of wound



CASE STUDY 2

86 year old male patient suffering from diabetes, cardiac insufficiency and asthma. At inclusion, he presented with a 6 month old, recurrent venous leg ulcer on the left leg. The wound was deteriorating under the previous treatment. The wound had become oedematous, the peri-wound skin flaked and the patient experienced pain in the wound area. He was treated with the **NOSF absorbent lipido-colloid dressing*** and a two layer compression therapy for 6 weeks.



CONCLUSION

The **new NOSF absorbent lipido-colloid dressing*** showed good results in a high number of patients presenting wounds at risk of delayed healing. The wound healing was kick-started due to the inhibition of MMP and a very fast and considerable reduction of wound surface area was achieved in most cases. The use of this new dressing in the treatment of wounds at risk of delayed healing should be considered.

Declaration of interest: This study was sponsored by Laboratoires Urgo.

* Brand name: The NOSF absorbent lipido-colloid dressing* is UrgoCell® START (Cellostart) from Laboratoires URGO.